News and Media
News and Media
BioAlliance Pharma reports its consolidated turnover for Q3 And announces progress for Loramyc® commercialization in Italy
November 14, 2011
Consolidated accounts for the first semester of 2011 and recent significant key events
September 21, 2011
Q2 2011: BioAlliance Pharma accelerates the progress of its “Orphan oncology products” portfolio and pursues its international partnerships on its “Specialty products”
July 28, 2011
Q1 2011: achievement of key milestones in BioAlliance Pharma’s clinical development program
May 13, 2011
Full-year financial results for 2010
March 3, 2011
Consolidated turnover for 2010
February 10, 2011
The structure of BioAlliance Pharma’s turnover for Q3 2010 reflects the dynamism of the company’s American and European collaborations
October 21, 2010
Consolidated accounts for the first semester of 2010
August 25, 2010
A record turnover for Q2 2010 reflecting the successful US FDA approval
July 22, 2010
Q1 2010 reflects the new European partnership agreement with Therabel Expected recurrent revenues
April 22, 2010
[wd_hustle id=”2″ type=”embedded”/]
